vs
STANDARD BIOTOOLS INC.（LAB）与EVERSPIN TECHNOLOGIES INC.（MRAM）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是EVERSPIN TECHNOLOGIES INC.的1.3倍（$19.6M vs $14.9M），EVERSPIN TECHNOLOGIES INC.净利率更高（-2.0% vs -177.4%，领先175.4%），EVERSPIN TECHNOLOGIES INC.同比增速更快（13.2% vs -11.5%），过去两年EVERSPIN TECHNOLOGIES INC.的营收复合增速更高（18.2% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Everspin Technologies是一家总部位于美国亚利桑那州钱德勒的上市半导体企业，核心业务为研发生产磁阻随机存取存储器（MRAM）产品，涵盖Toggle MRAM与自旋转移矩MRAM两大产品系列，同时也对外授权嵌入式MRAM、磁传感器相关技术，并提供嵌入式MRAM后道代工服务。
LAB vs MRAM — 直观对比
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $14.9M |
| 净利润 | $-34.7M | $-296.0K |
| 毛利率 | 48.5% | 52.7% |
| 营业利润率 | -168.5% | 29.0% |
| 净利率 | -177.4% | -2.0% |
| 营收同比 | -11.5% | 13.2% |
| 净利润同比 | -28.8% | — |
| 每股收益（稀释后） | $-0.09 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $14.9M | ||
| Q4 25 | — | $14.8M | ||
| Q3 25 | $19.6M | $14.1M | ||
| Q2 25 | $21.8M | $13.2M | ||
| Q1 25 | $40.8M | $13.1M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $22.1M | $12.1M | ||
| Q2 24 | $22.5M | $10.6M |
| Q1 26 | — | $-296.0K | ||
| Q4 25 | — | $1.2M | ||
| Q3 25 | $-34.7M | $54.0K | ||
| Q2 25 | $-33.5M | $-670.0K | ||
| Q1 25 | $-26.0M | $-1.2M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | $-26.9M | $2.3M | ||
| Q2 24 | $-45.7M | $-2.5M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | — | 50.8% | ||
| Q3 25 | 48.5% | 51.3% | ||
| Q2 25 | 48.8% | 51.3% | ||
| Q1 25 | 48.4% | 51.4% | ||
| Q4 24 | — | 51.3% | ||
| Q3 24 | 54.9% | 49.2% | ||
| Q2 24 | 46.1% | 49.0% |
| Q1 26 | — | 29.0% | ||
| Q4 25 | — | -7.2% | ||
| Q3 25 | -168.5% | -11.0% | ||
| Q2 25 | -118.1% | -14.9% | ||
| Q1 25 | -80.8% | -14.7% | ||
| Q4 24 | — | -11.8% | ||
| Q3 24 | -120.9% | -17.5% | ||
| Q2 24 | -134.5% | -26.5% |
| Q1 26 | — | -2.0% | ||
| Q4 25 | — | 8.1% | ||
| Q3 25 | -177.4% | 0.4% | ||
| Q2 25 | -153.7% | -5.1% | ||
| Q1 25 | -63.8% | -8.9% | ||
| Q4 24 | — | 9.2% | ||
| Q3 24 | -122.0% | 18.8% | ||
| Q2 24 | -203.3% | -23.5% |
| Q1 26 | — | $-0.01 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | $-0.09 | $0.00 | ||
| Q2 25 | $-0.09 | $-0.03 | ||
| Q1 25 | $-0.07 | $-0.05 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $-0.07 | $0.10 | ||
| Q2 24 | $-0.12 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $40.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $70.2M |
| 总资产 | $539.6M | $83.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $40.5M | ||
| Q4 25 | — | $44.5M | ||
| Q3 25 | $129.4M | $45.3M | ||
| Q2 25 | $158.6M | $45.0M | ||
| Q1 25 | $150.9M | $42.2M | ||
| Q4 24 | — | $42.1M | ||
| Q3 24 | $210.6M | $39.6M | ||
| Q2 24 | $269.8M | $36.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — |
| Q1 26 | — | $70.2M | ||
| Q4 25 | — | $68.9M | ||
| Q3 25 | $399.7M | $65.8M | ||
| Q2 25 | $424.5M | $64.1M | ||
| Q1 25 | $454.6M | $63.0M | ||
| Q4 24 | — | $62.6M | ||
| Q3 24 | $489.3M | $59.3M | ||
| Q2 24 | $510.3M | $55.4M |
| Q1 26 | — | $83.2M | ||
| Q4 25 | — | $84.6M | ||
| Q3 25 | $539.6M | $80.3M | ||
| Q2 25 | $557.0M | $78.9M | ||
| Q1 25 | $579.6M | $80.2M | ||
| Q4 24 | — | $77.8M | ||
| Q3 24 | $681.5M | $72.6M | ||
| Q2 24 | $708.7M | $64.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $570.0K |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $570.0K | ||
| Q4 25 | — | $2.6M | ||
| Q3 25 | $-22.2M | $881.0K | ||
| Q2 25 | $-20.7M | $5.0M | ||
| Q1 25 | $-30.3M | $1.4M | ||
| Q4 24 | — | $3.8M | ||
| Q3 24 | $-27.9M | $2.8M | ||
| Q2 24 | $-39.0M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-975.0K | ||
| Q3 25 | $-23.1M | $543.0K | ||
| Q2 25 | $-22.6M | $3.0M | ||
| Q1 25 | $-35.3M | $527.0K | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | $-30.1M | $2.8M | ||
| Q2 24 | $-41.0M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | -6.6% | ||
| Q3 25 | -118.1% | 3.9% | ||
| Q2 25 | -103.6% | 22.9% | ||
| Q1 25 | -86.6% | 4.0% | ||
| Q4 24 | — | 15.8% | ||
| Q3 24 | -136.4% | 22.9% | ||
| Q2 24 | -182.2% | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 24.3% | ||
| Q3 25 | 4.5% | 2.4% | ||
| Q2 25 | 8.7% | 15.1% | ||
| Q1 25 | 12.4% | 6.9% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | 10.2% | 0.5% | ||
| Q2 24 | 8.6% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.19× | ||
| Q3 25 | — | 16.31× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.16× | ||
| Q3 24 | — | 1.25× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
